Celgene's Revlimid wins additional FDA lymphoma approval

(Reuters) - Celgene Corp said on Wednesday that its flagship blood cancer drug, Revlimid, was approved by U.S. health regulators to treat mantle cell lymphoma, adding another revenue source for the $4 billion-a-year medicine. The U.S. Food and Drug Administration approved Revlimid to treat mantle cell lymphoma (MCL) - a type of non-Hodgkin's lymphoma - that has relapsed or progressed following two prior treatment regimens, one of which must include Takeda Pharmaceutical Co's Velcade. ... via Health News Headlines - Yahoo! News Read More Here..

For a Free Step By Step Guide for Dating Dos and Don'ts check http://end2endwebs.com

Lake forest health and fitness http://healthandfitness1blog.blogspot.com/2013/06/celgene-revlimid-wins-additional-fda.html